Inovio Pharmaceuticals
Update in progressINO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Inovio Pharmaceuticals is a biotechnology company developing DNA medicines to prevent and treat HPV-related diseases, cancer, and infectious diseases. Its SynCon plasmid DNA platform and CELLECTRA delivery devices enable administration of DNA medicines. Lead candidate INO-3107 targets HPV-related recurrent respiratory papillomatosis (Phase 1/2). Its pipeline includes VGX-3100, INO-3112, INO-5401, INO-4201, INO-4800, and INO-6160 in early trials. Based in Plymouth Meeting, PA, founded 1983.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Jacqueline E. Shea Ph.D.
- Founded1983
- Employees112
- Websitewww.inovio.com
Identifiers
- ISINUS45773H4092
- FIGIBBG000BK6YX5
- CUSIP371916107
- CIK0001055726